1-[2-[(2,6-dichloro-3-methylphenyl)amino]phenyl]ethanone | 23189-26-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[2-[(2,6-dichloro-3-methylphenyl)amino]phenyl]ethanone
• 英文别名: 1-[2-(2,6-dichloro-3-methylanilino)phenyl]ethanone
• CAS: 23189-26-6
• 化学式: C₁₅H₁₃Cl₂NO
• 分子量: 294.18
• InChiKey: NVCRDSLNYHAGIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-[2-[(2,6-dichloro-3-methylphenyl)amino]phenyl]ethanone 在 盐酸羟胺 作用下， 以 吡啶 、 水 为溶剂， 以0.2 g (24%)的产率得到1-[2-[(2,6-dichloro-3-methylphenyl)amino]phenyl]ethanone oxime
  参考文献：
  名称：

  N-hydroxyamide, N-hydroxythioamide, hydroxyurea, and N-hydroxythiourea

  摘要：

  本发明包括N-羟基酰胺、N-羟基脲、N-羟基硫代酰胺和N-羟基硫代脲衍生物，作为环氧合酶和5-脂氧合酶的双重抑制剂或选择性抑制剂，其中包括芬氨酸酯、吲哚美辛、环丙酚、奥克西那克和印多普酚。

  公开号：

  US04981865A1
• 作为产物：
  描述：

  丙二酸单乙酯 、 甲氯芬那酸 、 N,N'-羰基二咪唑 在 三氟乙酸 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 生成 1-[2-[(2,6-dichloro-3-methylphenyl)amino]phenyl]ethanone
  参考文献：
  名称：

  N-hydroxyamide, N-hydroxythioamide, hydroxyurea, and N-hydroxythiourea

  摘要：

  本发明包括N-羟基酰胺、N-羟基脲、N-羟基硫代酰胺和N-羟基硫代脲衍生物，作为环氧合酶和5-脂氧合酶的双重抑制剂或选择性抑制剂，其中包括芬氨酸酯、吲哚美辛、环丙酚、奥克西那克和印多普酚。

  公开号：

  US04981865A1

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION
  申请人：KANDULA Mahesh

  公开号：US20150148306A1

  公开（公告）日：2015-05-28

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of inflammation may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of Type II diabetes, Type I diabetes, insulin resistance, cardiovascular disease, arrhythmia, atherosclerosis, coronary artery disease, hypertriglyceridemia, dyslipidemia, retinopathy, nephropathy, neuropathy, macular adema, arthritis, osteoarthritis, rheumatoid arthritis, inflammatory bowel syndrome, neudegeneration, Alzheimer's disease, Huntington's disease, Ulcerative colitis, Crohn's disease, Multiple Sclerosis, muscular dystropthy, metabolic syndrome, fatty liver, bone diseases, inflammatory diseases.

  该发明涉及公式I的化合物或其药用可接受的盐，以及其多晶形、溶剂合物、对映体、立体异构体和水合物。包括有效量的公式I化合物的药物组合物，以及用于治疗炎症的方法可以制成口服、颊部、直肠、局部、经皮、经粘膜、静脉、肠内、糖浆或注射剂。这些组合物可用于治疗II型糖尿病、I型糖尿病、胰岛素抵抗、心血管疾病、心律失常、动脉粥样硬化、冠状动脉疾病、高三酰甘油血症、脂质代谢异常、视网膜病变、肾病、神经病变、黄斑水肿、关节炎、骨关节炎、类风湿性关节炎、炎症性肠病、神经退行性疾病、阿尔茨海默病、亨廷顿病、溃疡性结肠炎、克罗恩病、多发性硬化症、肌肉萎缩症、代谢综合征、脂肪肝、骨疾病、炎症性疾病的治疗。
• N-hydroxyamide, N-hydroxythioamide, N-hydroxyurea, and N-hydroxythiourea
  申请人：Warner-Lambert Co.

  公开号：US05075330A1

  公开（公告）日：1991-12-24

  The present invention includes N-hydroxyamide, N-hydroxyurea, N-hydroxythioamide, and N-hydroxythiourea derivatives of fenamates, indomethacin, cicloprofen, oxepinac, and indoprofen as dual inhibitors or selective ihibitors of cyclooxygenase and 5-lipoxygenase.

  本发明包括苯酰胺、尿素、硫代苯酰胺和硫代尿素衍生物的N-羟基衍生物，它们是环氧合酶和5-脂氧合酶的双重抑制剂或选择性抑制剂，其中包括芬氨酸、吲哚美辛、环丙酚、氧氟沛和印托芬。
• HYDROGELATORS COMPRISING D-AMINO ACIDS
  申请人：BRANDEIS UNIVERSITY

  公开号：US20150306232A1

  公开（公告）日：2015-10-29

  Described herein are compounds comprising an oligopeptide and a non-steroidal antiinflammatory agent. The compounds self-assemble into supramolecular hydrogels and can be used as topical treatments for inflammatory conditions, such as osteoarthritis. Also described herein are oligopeptides compounds made from D-amino acid residues that form supramolecular hydrogels. The compounds may be functionalized with active agents, such as anticancer therapeutic agents, antiinflammatory agents, or imaging agents, therefore providing new mechanisms for delivery of active agents.

  本文描述了包含寡肽和非甾体抗炎药物的化合物。这些化合物自组装成超分子水凝胶，并可用作局部治疗炎症疾病，如骨关节炎。本文还描述了由D-氨基酸残基制成的寡肽化合物，形成超分子水凝胶。这些化合物可与活性剂（如抗癌治疗剂、抗炎剂或成像剂）功能化，因此提供了新的活性剂传递机制。
• REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION
  申请人：Studiengesellschaft Kohle mbH

  公开号：EP3650446A1

  公开（公告）日：2020-05-13

  The present invention refers to a process for direct C-H functionalization, the reagents used in the process and the use thereof for the direct C-H functionalization as well as the so-obtained products.

  本发明涉及一种直接 C-H 功能化工艺、该工艺中使用的试剂、其在直接 C-H 功能化中的用途以及由此获得的产品。
• NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE
  申请人：Vizioli Ednir de Oliveira

  公开号：US20110118303A1

  公开（公告）日：2011-05-19

  The present invention relates to compounds derived from taurine with non-steroidal anti inflammatory activity. In a first embodiment, the present invention relates to compounds derived from taurine, in which taurine is bound directly by means of an amide bond or through an spacing group, to a compound selected from the group of non-steroidal anti inflammatory compounds, cited as derived from taurine presenting the Formula (I): in which R means the component with non-steroidal anti inflammatory activity. In a second embodiment, the invention provides a process for obtaining the compounds of Formula (I) by reaction of taurine with a compound belonging to the group of non-steroidal anti inflammatory (NSAIs), in order to obtain a compound derived from taurine by direct bond or through a spacing group of the taurine to the NSAI. The invention also relates to the pharmaceutical compositions comprising at least one compound derived from taurine presenting non-steroidal anti inflammatory activity.